Panasonic Announces Signing of Professional Women’s Tennis Player Naomi Osaka as Brand Ambassador
24.6.2021 10:48:00 EEST | Business Wire | Press release
Panasonic Corporation has signed a brand ambassador agreement with professional women's tennis player Naomi Osaka. The period of agreement is two years starting from April 22, 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005399/en/
Panasonic’s Brand Ambassador Naomi Osaka (Graphic: Business Wire)
Panasonic sought the agreement with Ms. Osaka after observing that her values and perspectives on society deeply resonate with its own management philosophy, primarily with regard to the following three points:
First, Ms. Osaka takes social issues seriously, looking beyond tennis to share her views on what a better society would look like in her own words. The founder of Panasonic, Konosuke Matsushita, held the notion that a stable state of happiness comes only when both mental stability and material prosperity are secured. Based on this idea, the company endeavors to create an ideal society where all of us can enjoy lives that are both mentally fulfilling and affluent in the material sense.
Second, Ms. Osaka’s intense and powerful playing is a source of energy and courage for people all over the world. Panasonic has passed down the founder’s view that the mission of an enterprise is to achieve a prosperous society and to make people happy, and continues to work toward fulfilling a strong aspiration not only to provide products needed by society, but also to make customers who use them feel happy and uplifted.
And third, Ms. Osaka continues to grow and evolve as her magnificent track record being one of the world’s top athletes is the result of her tireless efforts to refine each and every move in the course of her daily training and matches. Panasonic also continues to grow and evolve in a range of fields, aiming to elevate its expertise for the benefit of customers and society and achieve constant evolution.
At this time, Panasonic and Ms. Osaka have concluded a brand ambassador agreement to join hands in an endeavor to create an ideal society for each and every person, positioning “A Champion. For Progress.” as our shared commitment.
Ms. Osaka has shown she has the courage to take action in the face of adversity. Panasonic will provide her with heartfelt support.
Reference:
- Panasonic’s management philosophy
https://www.panasonic.com/global/corporate/management/philosophy.html#section_02
- Why Panasonic Appointed Naomi Osaka
https://channel.panasonic.com/contents/33222/
- "A CHAMPION. FOR PROGRESS." - Naomi Osaka, a brand ambassador of Panasonic
https://channel.panasonic.com/contents/33217/
https://channel.panasonic.com/contents/33219/ (Short version)
Naomi Osaka
Profile:
Date of birth: October 16, 1997
Place of birth: Osaka City, Osaka
Height: 180 cm
Naomi Osaka was born to a Japanese mother and a Haitian-American father, who moved her to New York in the United States when she was three years old. She is now based in Florida.
Major achievements:
- 2013: Started her professional career in tennis
- July 2014: Qualified for the first time for the Women’s Tennis Association (WTA) Tour Championships in Stanford
- January 2016: Advanced to the third round at the Australian Open, her Grand Slam debut
- 2016: Also advanced to the third round at the French Open (Roland-Garros) and the US Open Tennis Championships, where she recorded a serve speed of 201.1 km/h
- September 2016: Toray Pan Pacific Open Tennis Tournament runner-up
- October 2016: Named “Newcomer of the Year” at the 2016 WTA Awards, becoming the first Japanese player to win the award
- March 2018: BNP Paribas Open champion
- August 2018: US Open Tennis Championships champion
- January 2019: Australian Open champion
- September 2019: China Open tennis champion
- September 2019: Toray Pan Pacific Open Tennis Tournament champion
- August 2020: US Open Tennis Championships champion
- February 2021: Australian Open champion
Current WTA Ranking: 2nd
Qualified to play at the Olympic Games Tokyo 2020 (Women’s tennis, singles)
About Panasonic
Panasonic Corporation is a global leader developing innovative technologies and solutions for wide-ranging applications in the consumer electronics, housing, automotive, and B2B sectors. The company, which celebrated its 100th anniversary in 2018, operates 522 subsidiaries and 69 associated companies worldwide and reported consolidated net sales of 6,698.8 billion yen for the year ended March 31, 2021. Committed to pursuing new value through collaborative innovation, the company uses its technologies to create a better life and a better world for customers. Learn more about Panasonic: https://www.panasonic.com/global
Source: https://news.panasonic.com/global/press/data/2021/06/en210624-3/en210624-3.html
Related Links
- Panasonic’s management philosophy
https://www.panasonic.com/global/corporate/management/philosophy.html#section_02
- Why Panasonic Appointed Naomi Osaka
https://channel.panasonic.com/contents/33222/
- "A CHAMPION. FOR PROGRESS." - Naomi Osaka, a brand ambassador of Panasonic
https://channel.panasonic.com/contents/33217/
https://channel.panasonic.com/contents/33219/ (Short version)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005399/en/
Contact information
Panasonic Corporation
Corporate PR Department
Click here to go to Media Contact form
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom